Hemoglobin Based Oxygen Therapeutics in Elective Percutaneous Coronary Revascularization
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The test compound and subject of this clinical trial is the haemoglobin-based oxygen carrier,
HBOC-201 (Hemopure). HBOC-201, initially developed as an alternative to red blood cells for
surgical patients, has the ability to restore tissue oxygenation in persistently ischemic
tissue. The development of this new class of compounds, referred to as oxygen therapeutics,
provides an opportunity to test the safety and efficacy of a new approach to management of
myocardial ischemia.